Literature DB >> 15527639

Morbid obesity and gastric bypass surgery: biochemical profile.

V Silvestre1, M Ruano, Y Domínguez, R Castro, M C G García-Lescun, A Rodríguez, A Marco, G García-Blanch.   

Abstract

BACKGROUND: Morbid obesity (MO) and the pathologies associated with it constitute an important public health problem, accounting for 7% of the health expenditure in industrialized countries. An important percentage of this expense is attributed to the different biochemical tests performed in these patients, who suffer from several metabolic derangements. We evaluated the basic biochemical abnormalities in MO patients and their reversibility by weight loss after gastric bypass, to standardize the surveillance of the different metabolic abnormalities in obese patients.
METHODS: By a retrospective analysis on 125 patients operated in our hospital, we evaluated anthropometric and biochemical data before and 1, 3, 6, 12 and 24 months after gastric bypass.
RESULTS: Preoperatively hyperinsulinemia, hyperglycemia, dyslipidemia and hypertensive disease were present, and began to improve 1 and 3 months after surgery (although not significantly) and significantly at 6, 12 and 24 months after it. We also observed deficient protein nutrition and a deficiency of micronutrients both before bypass and during the follow-up.
CONCLUSION: After gastric bypass, a marked decrease in insulin occurred, with normalization of blood pressure and the biochemical parameters associated with the metabolic syndrome. We propose a biochemical follow-up protocol for MO patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15527639     DOI: 10.1381/0960892042387048

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  7 in total

1.  Effects of Weight Reduction After Sleeve Gastrectomy on Metabolic Variables in Saudi Obese Subjects in Aseer Province of Kingdom of Saudi Arabia.

Authors:  Mohammed A Bawahab; Abdullah S Assiri; Walid Abdel Maksoud; Ayyub Patel; Osama Kadoumi; Gaffar Sarwar Zaman; Riyad Mohammed Khalil Alessih; Syed Saleem Haider
Journal:  Obes Surg       Date:  2017-08       Impact factor: 4.129

2.  Long-term control of type 2 diabetes mellitus and the other major components of the metabolic syndrome after biliopancreatic diversion in patients with BMI < 35 kg/m2.

Authors:  Nicola Scopinaro; Francesco Papadia; Giuseppe Marinari; Giovanni Camerini; Gianfranco Adami
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

3.  Changes in lipid profile and insulin resistance in obese patients after Scopinaro biliopancreatic diversion.

Authors:  Magdalena Vila; Olga Ruíz; Mar Belmonte; Maria Riesco; Antonia Barceló; Gerardo Perez; Jose Moreiro; Ramon Salinas
Journal:  Obes Surg       Date:  2009-01-06       Impact factor: 4.129

4.  A rat model of childhood diet-induced obesity: Roux-en-Y gastric bypass induced changes in metabolic parameters and gastric peptide ghrelin.

Authors:  Charles J Aprahamian; Gonça Tekant; Min Chen; Ayden Yagmurlu; Ying-Kui Yang; Tara Loux; Carroll M Harmon
Journal:  Pediatr Surg Int       Date:  2007-05-16       Impact factor: 1.827

Review 5.  Iron, Vitamin B12, Folate and Copper Deficiency After Bariatric Surgery and the Impact on Anaemia: a Systematic Review.

Authors:  Carrie-Anne Lewis; Susan de Jersey; Matthew Seymour; George Hopkins; Ingrid Hickman; Emma Osland
Journal:  Obes Surg       Date:  2020-08-12       Impact factor: 4.129

6.  Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study.

Authors:  Simone Gehrer; Beatrice Kern; Thomas Peters; Caroline Christoffel-Courtin; Ralph Peterli
Journal:  Obes Surg       Date:  2010-01-26       Impact factor: 4.129

7.  Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study.

Authors:  Maria Antonella Burza; Stefano Romeo; Anna Kotronen; Per-Arne Svensson; Kajsa Sjöholm; Jarl S Torgerson; Anna-Karin Lindroos; Lars Sjöström; Lena M S Carlsson; Markku Peltonen
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.